Alzheimer's drugs rejected as benefits 'too small to justify cost
The National Institute for Health and Care Excellence is standing by its earlier decision to turn down donanemab and lecanemab after considering new information.
Continue reading this article about Alzheimer's drugs rejected as benefits 'too small to justify cost
by Olivia Allhusen
NHS Forums - For daily discussion by NHS Staff.

The National Institute for Health and Care Excellence is standing by its earlier decision to turn down donanemab and lecanemab after considering new information.
Continue reading this article about Alzheimer's drugs rejected as benefits 'too small to justify cost
by Olivia Allhusen
NHS Forums - For daily discussion by NHS Staff.